FDA Grants Accelerated Approval for RYBREVANT FASPRO in Head and Neck Squamous Cell Carcinoma

The FDA granted Johnson & Johnson accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) to treat adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed during or after platinum-based chemotherapy and anti-PD-(L)1 therapy. The approval excludes HPV-associated oropharyngeal cancer and expands the drug’s use beyond its existing oncology indications. The article reports no financial figures or stock-price impact.